Zafeiridi E, McMichael A, Mirakhur A, McHenry M, Holmes C, McGuinness B. Are tumour necrosis factor inhibitor drugs associated with a lower risk of dementia? Int J Geriatr Psych. 2020 Jul;35(7):802-3. doi: 10.1002/gps.5297
Hill NL, Mogle J, Bell TR, Bhargava S, Wion RK, Bhang I. Predicting current and future anxiety symptoms in cognitively intact older adults with memory complaints. Int J Geriatr Psych. 2019 Dec;34(12):1874-82. doi: 10.1002/gps.5204
Farreny A, Aguado J, Ochoa S, Haro JM, Usall J. The role of negative symptoms in the context of cognitive remediation for schizophrenia. Schizophr Res. 2013 Oct;150(1):58-63.
Farreny A, Aguado J, Ochoa S, Huerta-Ramos E, Marsà F, López-Carrilero R, Carral V, Haro JM, Usall J. REPYFLEC cognitive remediation group training in schizophrenia: looking for an integrative approach. Schizophr Res. 2012 Dec;142(1-3):137-44. doi: 10.1016/j.schres.2012.08.035.
Graham CN, Mauskopf J, Lawson AH, Ascher-Svanum H, Bruhn D, Watson PR. Validating an industry-sponsored model comparing the cost-effectiveness of atypical antipsychotics in the treatment of schizophrenia. Schizophr Res. 2010 Apr 1;117(2-3):398-9.